Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.11, read 2026-11-05
Ethical passes the values gate
Price31.06 USD
Fair value35.58
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-21Read Accumulation25.49+21.9% to today ✓Markdown gives way to Accumulation
2026-09-09Read Markdown26.37+17.8% to today Markup gives way to Markdown after a 5% rise in 5 weeks
2026-08-08Read Markup25.02+24.1% to today ✓Markdown gives way to Markup after a 5% slide in 5 weeks
2026-07-02Read Markdown26.46+17.4% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Koninklijke Philips NV ADR holds its Accumulation at $31.06. The statistical read favours the buyers, held for 162 days.
As held on the ledger · 2026-11-04
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 162 days
Price at the screen
$31.06
Valuation
19.83 trailing · 14.03 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.92
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.99%
Below 33%
Interest-bearing debt is just 29.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.20%
Below 33%
Cash held in interest-bearing accounts and securities is 1.2% of assets, under the one-third limit.
Pass
Receivables
22.76%
Below 49%
Money owed to the company is 22.8% of assets, under the 49% limit.
Pass
Revenue purity
0.47%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Koninklijke Philips clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 29%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PHG's ethical verdict changes
Today PHG passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 13% discount to our $35.58 fair value, narrow competitive moat, 0.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 12.7% discount to the base estimate.
Where our models see it going: fair-value estimate $35.58, with a range of $31.25 to $52.08, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Philips Devices Need Growth Not Just Discounts
Picture a hospital ordering fresh scanners while revenue at the supplier slips five percent. That is the reality at Philips right now. The shares trade at a forty percent discount to our fair value and the forward multiple sits at thirteen times, yet the business shows no real momentum.
We pass for a simple reason. Revenue is shrinking, returns on equity are only eight percent and the moat is narrow. A hold rating from analysts and a thirty one dollar median target line up with the lack of conviction. Ethical checks clear, but that alone does not create an opportunity.
The main risks are execution on the turnaround and pressure on margins that already sit at five percent. Without sustained top line growth the discount may simply reflect a company treading water. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Netherlands and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PHG trades on the NYSE (the company is based in Netherlands). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$28.46+7.1%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.
2026-10-28Accumulation$26.57+4.2%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.
2026-10-14Markdown$24.24-2.7%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.
2026-10-02Markdown$24.90-5.6%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.
2026-09-09Markdown · changed$26.37+5.4%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.
2026-08-08Markup · changed$25.02-5.4%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.
2026-07-18Markdown$26.46+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 12%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $34.
2026-07-03Markdown$26.46+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$26.46Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
